Dr. Reddy’s Laboratories Ltd. announced its unaudited financial results for the year ended March 31, 2009 under International Financial Reporting Standards (IFRS). Its FY09 contains following key points:
Overall revenues at Rs. 69.4 billion ($1.4 billion) in FY09 as against Rs. 50.0 billion ($983 million) in FY08, representing a growth of 39%.
The growth was driven by the successful launch of the authorized generic version of GlaxoSmithKline’s Imitrex